{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Cervical+Carcinoma",
    "query": {
      "condition": "Unresectable Cervical Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 157,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Cervical+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T15:09:39.711Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05669664",
      "title": "Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Salivary Gland Carcinoma",
        "Metastatic Salivary Gland Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Unresectable Salivary Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2023-07-20",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 27,
      "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 21 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05669664"
    },
    {
      "nct_id": "NCT00040911",
      "title": "Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Tumors",
        "Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Head and Neck Cancer",
        "Lymphoma",
        "Nausea",
        "Vomiting",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "electroacupuncture therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "sham intervention",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "5 Years to 35 Years"
      },
      "enrollment_count": 17,
      "start_date": "2005-04",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2013-05-31",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040911"
    },
    {
      "nct_id": "NCT00410761",
      "title": "An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "ZD6474 (Vandetanib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 331,
      "start_date": "2006-11-23",
      "completion_date": "2024-07-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 32,
      "location_summary": "Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00410761"
    },
    {
      "nct_id": "NCT03008278",
      "title": "Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Esophageal Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Recurrent Esophageal Carcinoma",
        "Recurrent Gastric Carcinoma",
        "Recurrent Gastroesophageal Junction Adenocarcinoma",
        "Stage III Esophageal Cancer AJCC v7",
        "Stage III Gastric Cancer AJCC v7",
        "Stage IV Esophageal Cancer AJCC v7",
        "Stage IV Gastric Cancer AJCC v7",
        "Unresectable Esophageal Carcinoma",
        "Unresectable Gastric Carcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2018-02-06",
      "completion_date": "2025-08-13",
      "has_results": true,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 32,
      "location_summary": "Corona, California • Duarte, California • Lancaster, California + 24 more",
      "locations": [
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03008278"
    },
    {
      "nct_id": "NCT02003482",
      "title": "Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Postop IMRT for head/neck cancer",
          "type": "RADIATION"
        },
        {
          "name": "CT for Radiation Treatment Planning",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2006-05-09",
      "completion_date": "2018-03-26",
      "has_results": false,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02003482"
    },
    {
      "nct_id": "NCT00019513",
      "title": "Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Liver Cancer",
        "Lung Cancer",
        "Lymphoma",
        "Pancreatic Cancer",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "1998-08",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-23",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019513"
    },
    {
      "nct_id": "NCT05945823",
      "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer",
        "Esophageal Adenocarcinoma",
        "Esophageal Squamous Cell Cancer",
        "Siewert Type 1 GEJ Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Futibatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2023-07-13",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 16,
      "location_summary": "Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05945823"
    },
    {
      "nct_id": "NCT05136196",
      "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Locally Recurrent Head and Neck Squamous Cell Carcinoma",
        "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Locally Recurrent Laryngeal Squamous Cell Carcinoma",
        "Locally Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hypopharyngeal Squamous Cell Carcinoma",
        "Metastatic Laryngeal Squamous Cell Carcinoma",
        "Metastatic Melanoma",
        "Metastatic Oral Cavity Squamous Cell Carcinoma",
        "Metastatic Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Melanoma",
        "Stage III Hypopharyngeal Carcinoma AJCC v8",
        "Stage III Laryngeal Cancer AJCC v8",
        "Stage III Lip and Oral Cavity Cancer AJCC v8",
        "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IV Hypopharyngeal Carcinoma AJCC v8",
        "Stage IV Laryngeal Cancer AJCC v8",
        "Stage IV Lip and Oral Cavity Cancer AJCC v8",
        "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2022-12-06",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 222,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 173 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136196"
    },
    {
      "nct_id": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage III Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Gastric Cancer AJCC v8",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Locally Advanced Cervical Carcinoma",
        "Locally Advanced Endometrial Carcinoma",
        "Locally Advanced Gastric Adenocarcinoma",
        "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Head and Neck Squamous Cell Carcinoma",
        "Locally Advanced Hepatocellular Carcinoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Melanoma",
        "Locally Advanced Merkel Cell Carcinoma",
        "Locally Advanced Renal Cell Carcinoma",
        "Locally Advanced Skin Squamous Cell Carcinoma",
        "Locally Advanced Triple-Negative Breast Carcinoma",
        "Locally Advanced Unresectable Breast Carcinoma",
        "Locally Advanced Unresectable Cervical Carcinoma",
        "Locally Advanced Unresectable Gastric Adenocarcinoma",
        "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Unresectable Renal Cell Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Gastric Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Merkel Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Skin Squamous Cell Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Skin Squamous Cell Carcinoma",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Cervical Carcinoma",
        "Unresectable Endometrial Carcinoma",
        "Unresectable Gastric Adenocarcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Unresectable Hepatocellular Carcinoma",
        "Unresectable Lung Non-Small Cell Carcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Melanoma",
        "Unresectable Merkel Cell Carcinoma",
        "Unresectable Renal Cell Carcinoma",
        "Unresectable Skin Squamous Cell Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma",
        "Unresectable Urothelial Carcinoma",
        "Breast Adenocarcinoma",
        "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Neoantigen Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2022-03-31",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05269381"
    },
    {
      "nct_id": "NCT06003231",
      "title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Ovarian Neoplasms",
        "Endometrial Neoplasms",
        "Head and Neck Neoplasms"
      ],
      "interventions": [
        {
          "name": "disitamab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2023-11-14",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-25T15:09:39.711Z",
      "location_count": 73,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06003231"
    }
  ]
}